Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
Gerco den Hartog, Eric R. A. Vos, Lotus L. van den Hoogen, et al.
Clinical Infectious Diseases (2021) Vol. 73, Iss. 12, pp. 2155-2162
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients
Daryl Geers, Marc C. Shamier, Susanne Bogers, et al.
Science Immunology (2021) Vol. 6, Iss. 59
Open Access | Times Cited: 523
The RECOVAC Immune-response Study
Jan‐Stephan Sanders, Fréderike J. Bemelman, A. Lianne Messchendorp, et al.
(2021) Vol. Publish Ahead of Print
Open Access | Times Cited: 109
COVID-19 reinfections among naturally infected and vaccinated individuals
Sezanur Rahman, Md. Mahfuzur Rahman, Mojnu Miah, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 106
Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
Daniele Focosi, Fabrizio Maggi, Arturo Casadevall
Viruses (2022) Vol. 14, Iss. 2, pp. 187-187
Open Access | Times Cited: 88
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
Rosemary J. Boyton, Daniel M. Altmann
Nature reviews. Immunology (2021) Vol. 21, Iss. 12, pp. 762-768
Open Access | Times Cited: 98
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
Sjoukje F. Oosting, Astrid A.M. van der Veldt, Corine H. GeurtsvanKessel, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 12, pp. 1681-1691
Open Access | Times Cited: 98
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
Sabine Haggenburg, Birgit I. Lissenberg‐Witte, Rob van Binnendijk, et al.
Blood Advances (2022) Vol. 6, Iss. 5, pp. 1537-1546
Open Access | Times Cited: 55
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial
Marcia M. L. Kho, A. Lianne Messchendorp, Sophie C. Frölke, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 3, pp. 307-319
Open Access | Times Cited: 55
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
Lotus L. van den Hoogen, Gaby Smits, Cheyenne C. E. van Hagen, et al.
Vaccine (2022) Vol. 40, Iss. 15, pp. 2251-2257
Open Access | Times Cited: 46
Role of the humoral immune response during COVID-19: guilty or not guilty?
Melyssa Yaugel-Novoa, Thomas Bourlet, Stéphane Paul
Mucosal Immunology (2022) Vol. 15, Iss. 6, pp. 1170-1180
Open Access | Times Cited: 43
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
Margaretha Prins, Geert V.T. Roozen, Cilia R. Pothast, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 9
Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
Catharina Gerhards, Margot Thiaucourt, Maximilian Kittel, et al.
International Journal of Infectious Diseases (2021) Vol. 107, pp. 221-227
Open Access | Times Cited: 54
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant
Marcia M. L. Kho, Marlies E. J. Reinders, Carla C. Baan, et al.
Nephrology Dialysis Transplantation (2021) Vol. 36, Iss. 9, pp. 1761-1764
Open Access | Times Cited: 42
Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
Jan‐Stephan Sanders, A. Lianne Messchendorp, Rory D. de Vries, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e188-e199
Open Access | Times Cited: 38
Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Patricia Kaaijk, Verónica Olivo Pimentel, Maarten E. Emmelot, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India
T. S. Selvavinayagam, Anavarathan Somasundaram, Jerard Maria Selvam, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel
Vivian Glück, Sonja Grobecker, Josef Köstler, et al.
Infection (2021) Vol. 50, Iss. 2, pp. 439-446
Open Access | Times Cited: 36
Dynamics of IgG-avidity and antibody levels after Covid-19
Emma Löfström, Anna Eringfält, Arne Kötz, et al.
Journal of Clinical Virology (2021) Vol. 144, pp. 104986-104986
Open Access | Times Cited: 30
kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers
José F. Varona, Rodrigo Madurga, Francisco Peñalver, et al.
European Journal of Internal Medicine (2021) Vol. 89, pp. 97-103
Open Access | Times Cited: 29
Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys
Siyu Chen, Jennifer A. Flegg, Lisa J. White, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 9, pp. e1009436-e1009436
Open Access | Times Cited: 29
SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response
Eric R. A. Vos, Cheyenne C. E. van Hagen, Denise Wong, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 6
Open Access | Times Cited: 4
Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study
Minke R Holwerda, Christina E. Hoeve, Anne J. Huiberts, et al.
Eurosurveillance (2024) Vol. 29, Iss. 25
Open Access | Times Cited: 4
Dynamics of SARS-CoV-2 Immunoglobulin G Antibody Among Hospitalized Patients and Healthcare Workers During the Delta Wave in Bangladesh
Md. Abdul Matin, Chowdhury Adnan Sami, M. Anjan, et al.
Cureus (2025)
Open Access
Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands
Marije K. Verheul, Joanna Kaczorowska, Marloes I. Hofstee, et al.
Mucosal Immunology (2024) Vol. 17, Iss. 4, pp. 554-564
Closed Access | Times Cited: 3
IgG1 glycosylation highlights premature aging in Down syndrome
Bianca M. M. Streng, Julie Van Coillie, Joanne Wildenbeest, et al.
Aging Cell (2024) Vol. 23, Iss. 7
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top